Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 3/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838027 | 1.00 | CTBP2 (0.52) | CTBP2CES1CES2AKR1B1TSHR | |
| SCHEMBL838026 | 1.00 | CTBP2 (0.52) | CTBP2CES1CES2AKR1B1TSHR | |
| SCHEMBL510577 | 0.82 | ALDH1A1 (0.46) | CTBP2TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL509498 | 0.82 | AGXT (0.44) | CTBP2MGLL | |
| SCHEMBL510576 | 0.82 | ALDH1A1 (0.46) | CTBP2TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL509497 | 0.82 | AGXT (0.44) | CTBP2MGLL | |
| SCHEMBL1106861 | 0.82 | LTA4H (0.53) | TSHREPHX2 | |
| SCHEMBL510285 | 0.82 | LTA4H (0.53) | TSHREPHX2 | |
| SCHEMBL1106894 | 0.82 | SLC6A4 (0.46) | CTBP2MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL510335 | 0.82 | FFAR1 (0.53) | MEN1KMT2AMAPTALDH1A1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| EP-3555096-B1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-23 | — | — | EP | disclosed |
| EP-1888596-B1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8772307-B2 | Substituted spiro compounds and their use for producing pain-relief medicaments | GRUENENTHAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-8772307-B2 | Substituted spiro compounds and their use for producing pain-relief medicaments | GRUENENTHAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-8772307-B2 | Substituted spiro compounds and their use for producing pain-relief medicaments | GRUENENTHAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-8193192-B2 | Heterocyclic FXR binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2012-06-05 | — | — | US | disclosed |
| US-20100210660-A1 | Heterocyclic FXR Binding Compounds | PHENEX PHARMACEUTICALS AG (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100184809-A1 | Heterocyclic FXR Binding Compounds | PHENEX PHARMACEUTICALS AG (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | GRUENENTHAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-6018069-A | 2-isoxazoline derivative and process for producing the same and process for producing related derivatives from the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2000-01-25 | — | — | US | disclosed |
| US-5994558-A | 2-isoxazoline derivative and process for producing the same; and process for producing related derivatives from the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| US-5962692-A | 2-isoxazoline derivative and process for producing the same, and process for producing related derivatives from the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5750717-A | 2-isoxazoline derivative and process for producing the same, and process for producing related derivatives from the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5602160-A | MUSCLE RELAXANT | MITSUI TOATSU CHEMICALS INCORPORATED (JP) | 1997-02-11 | — | — | US | disclosed |
| EP-0748801-A1 | 2-ISOXAZOLINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME, AND PROCESS FOR PRODUCING RELATED DERIVATIVES FROM THE SAME | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-18 | — | — | EP | disclosed |
| US-5498619-A | MUSCLE RELAXANTS, POLLAKIUREA CURING AGENTS AND MUSCLE SPASMS | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1996-03-12 | — | — | US | disclosed |
| EP-0414391-B1 | Aminoketone derivatives and use thereof | MITSUI TOATSU CHEMICALS (JP) | 1995-03-15 | — | — | EP | disclosed |
| US-5338857-A | Muscle relaxant | MITSUI TOATSU CHEMICALS INCORPORATED (JP) | 1994-08-16 | — | — | US | disclosed |
| EP-0414391-A2 | Aminoketone derivatives and use thereof | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JAK1, JAK2, JAK3 | CTBP2 2583/4885CES1 3622/4885CES2 4739/4885 |
| US-20100210660-A1 | Heterocyclic FXR Binding Compounds | NR1H4, NR1I3, NR1I2 | CTBP2 1065/4885CES1 928/4885CES2 3798/4885 |
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | INA, SCN1A, SI | CTBP2 3751/4885CES1 1706/4885CES2 2260/4885 |
| US-20100184809-A1 | Heterocyclic FXR Binding Compounds | NR1H4, NR1H2, NR1H3 | CTBP2 1278/4885CES1 399/4885CES2 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.